Research
The Tät® II app has been evaluated in several research studies at Umeå University.
The results from a randomized controlled trial (RCT) on the effects of Tät® II showed that women with urge incontinence and mixed incontinence who used the app for 15 weeks improved in terms of incontinence symptoms, urgency symptoms, quality of life, number of leakages, use of incontinence aids, and catastrophizing, compared to a group that used an information app.
After treatment, 87% of the women who had used the app reported an improvement, compared with 30% in the control group.
The improvements in symptoms and quality of life remained at the same level when the women were followed up after one year.
A health economic analysis of Tät® II showed that the app offers a new and cost-effective first-line treatment option, which can increase access to care for a large group of women.
In a randomized controlled trial (RCT), bladder diaries completed by participants at the start and after 15 weeks of treatment were compared. The women who received the Tät® II treatment app urinated fewer times per day and leaked fewer times per day after 15 weeks of treatment. The degree of leakage and the intensity of urgency had decreased after 15 weeks of treatment. All improvements were statistically significant compared to the control group, which received a pure information app.